![]() |
Name |
(4S,8aR,9S,12S,12aR)-9,12-dihydroxy-4-methyl-1,4,5,6,7,8,8a,9,10,11,12,12a-dodecahydrobenzo[d]oxecin-2-one
|
Molecular Formula | C14H24O4 | |
IUPAC Name* |
(4S,8aR,9S,12S,12aR)-9,12-dihydroxy-4-methyl-1,4,5,6,7,8,8a,9,10,11,12,12a-dodecahydrobenzo[d]oxecin-2-one
|
|
SMILES |
C[C@H]1CCCC[C@H]2[C@H](CC[C@@H]([C@@H]2CC(=O)O1)O)O
|
|
InChI |
InChI=1S/C14H24O4/c1-9-4-2-3-5-10-11(8-14(17)18-9)13(16)7-6-12(10)15/h9-13,15-16H,2-8H2,1H3/t9-,10+,11+,12-,13-/m0/s1
|
|
InChIKey |
VDMSRLJJKGITNQ-QWQWKMKNSA-N
|
|
Synonyms |
LMA-P1; CHEMBL1761482
|
|
CAS | NA | |
PubChem CID | 52917997 | |
ChEMBL ID | CHEMBL1761482 |
Chemical Classification: |
|
|
---|
Molecular Weight: | 256.34 | ALogp: | 1.6 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 66.8 | Aromatic Rings: | 2 |
Heavy Atoms: | 18 | QED Weighted: | 0.652 |
Caco-2 Permeability: | -4.658 | MDCK Permeability: | 0.00008710 |
Pgp-inhibitor: | 0.202 | Pgp-substrate: | 0.941 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.498 |
Blood-Brain-Barrier Penetration (BBB): | 0.259 | Plasma Protein Binding (PPB): | 50.15% |
Volume Distribution (VD): | 0.712 | Fu: | 26.15% |
CYP1A2-inhibitor: | 0.035 | CYP1A2-substrate: | 0.095 |
CYP2C19-inhibitor: | 0.01 | CYP2C19-substrate: | 0.388 |
CYP2C9-inhibitor: | 0.006 | CYP2C9-substrate: | 0.532 |
CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.104 |
CYP3A4-inhibitor: | 0.027 | CYP3A4-substrate: | 0.183 |
Clearance (CL): | 11.59 | Half-life (T1/2): | 0.846 |
hERG Blockers: | 0.035 | Human Hepatotoxicity (H-HT): | 0.39 |
Drug-inuced Liver Injury (DILI): | 0.434 | AMES Toxicity: | 0.03 |
Rat Oral Acute Toxicity: | 0.02 | Maximum Recommended Daily Dose: | 0.517 |
Skin Sensitization: | 0.938 | Carcinogencity: | 0.699 |
Eye Corrosion: | 0.961 | Eye Irritation: | 0.786 |
Respiratory Toxicity: | 0.688 |